Octreotide is not effective in the acute treatment of migraine

Cephalalgia

Volumn 25, Issue 1, 2005, Pages 48-55

  Levy, M J ^a,b   Matharu, M S ^a   Bhola, R ^a   Meeran, K ^b   Goadsby, Peter J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Headache; Migraine; Neurovascular; Somatostatin

Indexed keywords

OCTREOTIDE; PLACEBO; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SEROTONIN AGONIST;

ACUTE DISEASE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; HYPERHIDROSIS; MALE; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NAUSEA; PAIN ASSESSMENT; PHOTOPHOBIA; RANDOMIZED CONTROLLED TRIAL; SELF MEDICATION; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; COHORT STUDIES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; OCTREOTIDE;

EID: 12444306458     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2004.00807.x     Document Type: Article

References (56)

1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine- current understanding and treatment. N Eng J Med 2002; 346:257-70.
2. 1B/1D agonists) in migraine. detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002; 22:633-58.
3. 1B/1D agonists) in acute migraine treatment. a meta-analysis of 53 trials. Lancet 2001; 358:1668-75.
4. Nappi G, Sandrini G, Sances G. Tolerability of the triptans: clinical implications. Drug Safety 2003; 26:93-107.
5. Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001; 57:1694-8.
6. Edvinsson L, Goadsby PJ. Neuropeptides in the cerebral circulation: relevance to headache. Cephalalgia 1995; 15:272-8.
7. Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 2000; 129:420-3.
8. Moreno MJ, Abounader R, Hebert E, Doods H, Hamel E. Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment. Neuropharmacology 2002; 42:568-76.
9. Olesen J, Diener H-C, Husstedt I, Goadsby PJ, Hall D, Meier U, et al. Calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS is effective in the treatment of migraine attacks. Cephalalgia 2003; 23:579.
10. Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein SD, Mathew NT. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 1997; 17:785-90.
11. 1 receptor antagonist in the acute treatment of migraine. Cephalalgia 1998; 18:392.
12. Norman B, Panebianco D, Block GA. A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 (a prodrug of the NK1 receptor antagonist L-754,030) in the acute treatment of migraine. Cephalalgia 1998; 18:407.
13. Diener H-C, The RPR100893 Study Group. RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia 2003; 23:183-5.
14. Goldstein DJ, Offen WW, Klein EG, Phebus LA, Hipskind P et al. Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia 2001; 21:102-6.
15. Ferrar JA, Cuthbert AW, Cox HM. The antisecretory effects of somatostatin and analogues in rat descending colon mucosa. Eur J Pharmacol 1990; 184:295-303.
16. Helyes Z, Pinter E, Nemeth J, Keri G, Than M, Oroszi G, et al. Anti-inflammatory effect of synthetic somatostatin analogues in the rat. Br J Pharmacol 2001; 134:1571-9.
17. Fassler JE, O'Dorisio TM, Mekhjian HS, Gaginella TS. Octreotide inhibits increases in short-circuit current induced in rat colon by VIP, substance P, serotonin and aminophylline. Reg Peptides 1990; 29:189-97.
18. Selmer I, Schindler M, Allen JP, Humphrey PP, Emsom PC. Advances in understanding neuronal somatostatin receptors. Reg Peptides 2000; 90:1-18.
19. Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut 1994; 35: S1-4.
20. Kapicioglu S, Gokce E, Kapicioglu Z, Ovali E. Treatment of migraine attacks with a long-acting somatostatin analogue (octreotide, SMS 201-995). Cephalalgia 1997; 17:27-30.
21. Tfelt-Hansen P, Block G, Dahlof C, Diener H-C, Ferrari MD, Goadsby PJ, et al. Guidelines for controlled trials of drugs in migraine: second edition. 2nd edition. Cephalalgia 2000; 20:765-86.
22. Davies GM, Santanello NC, Lipton RB. Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000; 20:554-60.
23. Lipton RB, Lieberman J, Goadsby PJ, Ferrari M, Dodick DW, Cutrer FM, et al. An assessment of the priorities of U.S. migraineurs with respect to pre-specified triptan treatment attributes. Headache 2002; 42:396.
24. Sicuteri F, Geppetti P, Marabini S, Lembeck F. Pain relief by somatostatin in attacks of cluster headache. Pain 1984; 18:359-65.
25. Pascual J, Freijares J, Berciano J, Pesquera C. Analgesic effect of octreotide in headache associated with acromegaly is not mediated by opioid mechanisms. Pain 1991; 47:341-4.
26. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 1992; 117:711-78.
27. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metabolism 1998; 83:303-440.
28. Williams G, Ball J, Bloom S, Joplin GF. Improvement in headache associated with prolactinoma during treatment with somatostatin analogue. an 'N of 1' study. Study N Eng J Medical 1986; 315:1166-7.
29. Williams G, Bali JA, Lawson RA, Joplin GF, Bloom SR, Maskill MR. Analgesic effect of somatostatin analogue (octreotide) in headache associated with pituitary tumours. Br Med J 1987; 295:247-8.
30. Chanson P, Timsit J, Harris AG. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin Pharmacokinetics 1993; 25:375-39.
31. Levy MJ, Barakat M, Bejon P, Goadsby PJ, Meeran K. Acromegaly: a unique human headache model? Headache 2003; 43:794-7.
32. Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PP, et al. Classification and nomenclature of somatostatin receptors. Trends Rhe Pharmacol Sci 1995; 16:86-8.
33. Patel YC, Srikant CB. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinol 1994; 135:2814-7.
34. Schindler M, Holloway S, Hathway G, Woolf CJ, Humphrey PP, Emson PC. Identification of somatostatin sst2 (a) receptor expressing neurones in central regions involved in nociception. Brain Res 1998; 798:25-35.
35. Kitazawa T, Terasaki T, Suzuki H, Kakee A, Sugiyama Y. Efflux of taurocholic acid across the blood-brain barrier: interaction with cyclic peptides. J Pharmacol Exp Ther 1998; 286:890-5.
36. Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrandt G, Klug N, et al. Somatostatin receptor imaging in intracranial tumours. European J Nuclear Med 1998; 25:675-86.
37. De Vries P, Villalon CM, Saxena PR. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur J Pharmacol 1999; 375:61-74.
38. Matharu MS, Levy MJ, Meeran K, Goadsby PJ. Subcutaneous octreotide is effective in the treatment of acute cluster headache: a double-blind placebo-controlled crossover study. Cephalalgia 2003; 23:580.
39. Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol 1991; 31:295-9.
40. Headache Classification Committee of The International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl 7:1-96.
41. Headache Classification Committee of The International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia 2004; 24 Suppl 1:1-160.
42. Ferrari MD, The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Eng J Med 1991; 325:316-21.
43. Snijders TAB, Bosker RJ. Multilevel Analysis. An Introduction to Basic and Advanced Multilevel Modelling, 1st edition. London: Sage Publications, 1999.
44. Yang M, Goldstein H, Heath A. Multilevel models for repeated binary outcomes: attitudes and voting over the electoral cycle. J Roy Statist Soc (A) 2000; 163:49-62.
45. van Vliet JA, Bahra A, Martin V, Aurora SK, Mathew NT et al. Intranasal sumatriptan in cluster headache-randomized placebo-controlled double-blind study. Neurology 2003; 60:630-3.
46. Koseoglu E, Nacar M, Talaslioglu A, Cetinkaya F. Epidemiological and clinical characteristics of migraine and tension type headache in 1146 females in Kayseri. Turkey Cephalalgia 2003; 23:381-8.
47. Stewart WF, Shechter A, Lipton RB. Migraine heterogeniety. disability, pain intensity, attack frequency and duration. Neurology 1994; 44 Suppl 4:24-39.
48. Lipton RB, Hamelsky S, Dayno J. What do patients with migraine want from acute migraine treatment? Headache 2002; 42:3-9.
49. Plockinger U, Dienemann D, Quabbe HJ. Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. J Clin Endocrinol Metabolism 1990; 71:1658-62.
50. Helmchen C, Fu QG, Sandkuhler J. Inhibition of spinal nociceptive neurons by microinjections of somatostatin into the nucleus raphe magnus and the midbrain periaqueductal gray of the anesthetized cat. Neurosci Lett 1995; 187:137-41.
51. Bereiter DA. Morphine and somatostatin analogue reduce c-FOS expression in trigeminal subnucleus caudalis produced by corneal stimulation in the rat. Neuroscience 1997; 77:863-74.
52. Schindler M, Humphrey PPA, Emson PC. Somatostatin receptors in the central nervous system. Prog Neurobiol 1996; 50:9-47.
53. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997; 100:2386-92.
54. Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, et al. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metabolism 2002; 87:5545-52.
55. Goadsby PJ. Pathophysiology of cluster headache: a trigeminal autonomic cephalgia. Lancet Neurol 2002; 1:37-43.
56. Ekbom K, The Sumatriptan Cluster Headache Study Group. Treatment of acute cluster headache with sumatriptan. N Eng J Med 1991; 325:322-6.